The chart shows how Biocon’s shares have done versus the broader markets since its listing in April 2004. An actual US/Europe market launch is the next milestone to be watched for and delays will cause anxiety. Will other products in Biocon’s pipeline get a similarly smooth pathway or was this a one-off event, is a question investors may ask. Its sales, profits and cash flows should see a significant increase as these products launch. If its pipeline delivers, they can also help lay the building blocks for Biocon’s next decade in this industry.

Source: Mint July 17, 2017 02:03 UTC